Elevated SFXN2 correlates with poor clinical outcomes in multiple myeloma and acute myeloid leukemia, potentially due to its regulations of mitochondrial iron metabolism, bioenergetics, autophagy, and redox homeostasis (Chen Y. et al., 2022). The gene discussed is SFXN2; the disease is AL amyloidosis.